Kezar Life Sciences, Inc. (NASDAQ:KZR – Get Rating) gapped down prior to trading on Thursday . The stock had previously closed at $9.67, but opened at $9.30. Kezar Life Sciences shares last traded at $9.62, with a volume of 728 shares changing hands.
Analysts Set New Price Targets
KZR has been the subject of a number of research analyst reports. Jonestrading boosted their price target on Kezar Life Sciences from $17.00 to $20.00 in a report on Tuesday, June 28th. HC Wainwright boosted their price target on Kezar Life Sciences from $20.00 to $21.00 and gave the stock a “buy” rating in a report on Friday, August 12th. Finally, Wells Fargo & Company boosted their price target on Kezar Life Sciences from $13.00 to $17.00 and gave the stock an “overweight” rating in a report on Tuesday, June 28th.
Kezar Life Sciences Price Performance
The firm has a market cap of $591.51 million, a P/E ratio of -9.41 and a beta of 0.15. The company has a current ratio of 39.64, a quick ratio of 39.64 and a debt-to-equity ratio of 0.03. The business has a 50-day moving average of $9.99 and a two-hundred day moving average of $10.46.
Institutional Investors Weigh In On Kezar Life Sciences
Institutional investors have recently made changes to their positions in the stock. New York State Common Retirement Fund grew its position in shares of Kezar Life Sciences by 34.2% in the 1st quarter. New York State Common Retirement Fund now owns 27,059 shares of the company’s stock valued at $450,000 after buying an additional 6,891 shares during the last quarter. EAM Global Investors LLC bought a new stake in shares of Kezar Life Sciences during the 4th quarter valued at about $3,123,000. Ghost Tree Capital LLC bought a new stake in shares of Kezar Life Sciences during the 4th quarter valued at about $4,180,000. Mendel Capital Management LLC bought a new stake in shares of Kezar Life Sciences during the 4th quarter valued at about $213,000. Finally, Skandinaviska Enskilda Banken AB publ bought a new stake in shares of Kezar Life Sciences during the 1st quarter valued at about $650,000. Institutional investors own 91.01% of the company’s stock.
About Kezar Life Sciences
Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis.
- Get a free copy of the StockNews.com research report on Kezar Life Sciences (KZR)
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
Receive News & Ratings for Kezar Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kezar Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.